UK medtech firm raises over £2m to deliver ophthalmic devices

Occuity hits investment target after just 24 hours, paving the way for further development of its ophthalmic and optical diabetes devices

Occuity is seeking funding to accelerate development of its optical devices which will help to detect a number of medical conditions

Occuity, a Thames Valley-based medical technology start-up, is celebrating after hitting its £1.8m investment target just 24 hours after launching on crowdfunding platform, Seedrs.

And, with the round still open, the company now plans to ‘overfund’ to allow it to accelerate development of its innovative optical devices.

Founded in 2019, Occuity has developed and patented its contactless optical technology to obtain precise measurements from the eye.

Occuity’s vision is to use the eye as a window to the health of the body and to utilise its non-invasive, non-contact, hand-held technology to bring a range of new medical devices to market which use this technology for ophthalmic examinations, diabetes management, pre-diabetes screening and, in the longer term, the early detection of Alzheimer’s disease.

Company chief executive and co-founder, Dr Dan Daly, said: “We’re delighted with the level of interest we have received during this finance round and are thrilled that we are now overfunding.

“To date we have now raised over £2m, which will allow us to accelerate the development of our new optical screening and monitoring devices which aim to detect the early signs of chronic health conditions by scanning the human eye.”

He added: “Diabetes is a very-personal issue and, of course, once you have it, it’s likely with you for the rest of your life.

“As our long-term products will be personal-use meters for people with diabetes, we wanted to give our community of 8,000 people with diabetes the opportunity to become full shareholders in our business and to join us on this journey to try to improve their lives.”

It contactless optical technology obtains precise measurements from the eye, providing a window to the health of the body

The rollout plan for Occuity’s new medical devices includes:

  • Occuity’s first device, the PM1 Pachymeter, is aimed at the optometry market and measures corneal thickness with micrometre level precision. This is due to begin clinical testing and is expected to be approved for use in the EU by early 2022
  • The company plans to launch a pre-diabetes screening device in 2024 to allow mass testing for the emerging signs of Type 2 diabetes at pharmacies and opticians
  • In 2025, it intends to introduce a personal non-invasive optical glucose monitor that will enable people with diabetes to monitor their blood-sugar levels without drawing blood
  • Occuity hopes that its research and development will also support the delivery of a routine screening device capable of detecting early signs of Alzheimer’s disease by identifying biomarkers deposited in the eye

Design director, Daniele De Iuliis, said: “The work we are doing at Occuity is hugely exciting, presenting the opportunity to deliver a step change over the next decade in optometry practice and the way chronic diseases like diabetes and Alzheimer’s are detected and managed.”

Companies